Delfi Diagnostics

Delfi’s technology leverages advancements in machine learning and recent discoveries in genome-wide fragmentation of cell-free DNA to create a new method for detecting tumor evidence from blood samples, while also identifying the location of tumors within the body. Delfi is applying this platform technology to develop a range of products aimed at detecting specific cancers, such as lung cancer, and identifying multiple cancers in any individual within high-risk populations.